Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Averbuch

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Lung Cancer|December 4, 2003
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancerSteven D Averbuch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?Patricia M LoRusso, Aparna B Anderson, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Translating clinical trials into meaningful outcomesPatricia M LoRusso, Lowell E Schnipper, David J Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal for Immunotherapy of Cancer|October 21, 2018
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Nature Reviews. Drug Discovery|November 1, 2011
Quantifying factors for the success of stratified medicineMark R Trusheim, Breon Burgess, Sean Xinghua Hu, et al.
JAMA|October 23, 2003
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialMark G Kris, Ronald B Natale, Roy S Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2Roy S Herbst, Giuseppe Giaccone, Joan H Schiller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1Giuseppe Giaccone, Roy S Herbst, Christian Manegold, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Lung Cancer|December 4, 2003
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancerSteven D Averbuch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?Patricia M LoRusso, Aparna B Anderson, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Translating clinical trials into meaningful outcomesPatricia M LoRusso, Lowell E Schnipper, David J Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal for Immunotherapy of Cancer|October 21, 2018
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Nature Reviews. Drug Discovery|November 1, 2011
Quantifying factors for the success of stratified medicineMark R Trusheim, Breon Burgess, Sean Xinghua Hu, et al.
JAMA|October 23, 2003
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialMark G Kris, Ronald B Natale, Roy S Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2Roy S Herbst, Giuseppe Giaccone, Joan H Schiller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1Giuseppe Giaccone, Roy S Herbst, Christian Manegold, et al.
Pageof 2